questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
Benzopyranes
Coumarines
4-Hydroxycoumarines
4-Hydroxycoumarines : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "4-Hydroxycoumarines : Questions médicales les plus fréquentes",
"headline": "4-Hydroxycoumarines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les 4-Hydroxycoumarines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-10",
"dateModified": "2025-04-04",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "4-Hydroxycoumarines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Coumarines",
"url": "https://questionsmedicales.fr/mesh/D003374",
"about": {
"@type": "MedicalCondition",
"name": "Coumarines",
"code": {
"@type": "MedicalCode",
"code": "D003374",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Acénocoumarol",
"alternateName": "Acenocoumarol",
"url": "https://questionsmedicales.fr/mesh/D000074",
"about": {
"@type": "MedicalCondition",
"name": "Acénocoumarol",
"code": {
"@type": "MedicalCode",
"code": "D000074",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.079"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dicoumarol",
"alternateName": "Dicumarol",
"url": "https://questionsmedicales.fr/mesh/D001728",
"about": {
"@type": "MedicalCondition",
"name": "Dicoumarol",
"code": {
"@type": "MedicalCode",
"code": "D001728",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.203"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Biscoumacétate d'éthyle",
"alternateName": "Ethyl Biscoumacetate",
"url": "https://questionsmedicales.fr/mesh/D005017",
"about": {
"@type": "MedicalCondition",
"name": "Biscoumacétate d'éthyle",
"code": {
"@type": "MedicalCode",
"code": "D005017",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.451"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phenprocoumone",
"alternateName": "Phenprocoumon",
"url": "https://questionsmedicales.fr/mesh/D010644",
"about": {
"@type": "MedicalCondition",
"name": "Phenprocoumone",
"code": {
"@type": "MedicalCode",
"code": "D010644",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Warfarine",
"alternateName": "Warfarin",
"url": "https://questionsmedicales.fr/mesh/D014859",
"about": {
"@type": "MedicalCondition",
"name": "Warfarine",
"code": {
"@type": "MedicalCode",
"code": "D014859",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.150.446.520.914"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "4-Hydroxycoumarines",
"alternateName": "4-Hydroxycoumarins",
"code": {
"@type": "MedicalCode",
"code": "D015110",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Li Sheng",
"url": "https://questionsmedicales.fr/author/Li%20Sheng",
"affiliation": {
"@type": "Organization",
"name": "Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China."
}
},
{
"@type": "Person",
"name": "Zahra Hosseini-Khah",
"url": "https://questionsmedicales.fr/author/Zahra%20Hosseini-Khah",
"affiliation": {
"@type": "Organization",
"name": "Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, Iran."
}
},
{
"@type": "Person",
"name": "Saeed Emami",
"url": "https://questionsmedicales.fr/author/Saeed%20Emami",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran. sdemami12@gmail.com."
}
},
{
"@type": "Person",
"name": "Jhonnathan Brawley",
"url": "https://questionsmedicales.fr/author/Jhonnathan%20Brawley",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Nevada, Reno, Nevada 89557-0216, United States."
}
},
{
"@type": "Person",
"name": "Amarawan Intasiri",
"url": "https://questionsmedicales.fr/author/Amarawan%20Intasiri",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Nevada, Reno, Nevada 89557-0216, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cascades in language acquisition: Re-thinking the linear model of development.",
"datePublished": "2023-01-31",
"url": "https://questionsmedicales.fr/article/37080675",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/bs.acdb.2022.11.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Language skills development in children with congenital Zika virus syndrome.",
"datePublished": "2023-08-09",
"url": "https://questionsmedicales.fr/article/37595539",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.earlhumdev.2023.105842"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sources of individual differences in the dual language development of heritage bilinguals.",
"datePublished": "2023-02-01",
"url": "https://questionsmedicales.fr/article/36722256",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1017/S0305000922000708"
}
},
{
"@type": "ScholarlyArticle",
"name": "Literacy and early language development: Insights from computational modelling.",
"datePublished": "2023-03-22",
"url": "https://questionsmedicales.fr/article/36946299",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1017/S0305000923000193"
}
},
{
"@type": "ScholarlyArticle",
"name": "Language development trajectories in young children with developmental disabilities in Taiwan.",
"datePublished": "2023-03-06",
"url": "https://questionsmedicales.fr/article/36889171",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ridd.2023.104470"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Benzopyranes",
"item": "https://questionsmedicales.fr/mesh/D001578"
},
{
"@type": "ListItem",
"position": 6,
"name": "Coumarines",
"item": "https://questionsmedicales.fr/mesh/D003374"
},
{
"@type": "ListItem",
"position": 7,
"name": "4-Hydroxycoumarines",
"item": "https://questionsmedicales.fr/mesh/D015110"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : 4-Hydroxycoumarines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur 4-Hydroxycoumarines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur 4-Hydroxycoumarines",
"description": "Comment diagnostiquer une surdose de 4-hydroxycoumarines ?\nQuels tests sont utilisés pour surveiller le traitement par 4-hydroxycoumarines ?\nQuels symptômes indiquent une complication du traitement ?\nComment évaluer l'efficacité des 4-hydroxycoumarines ?\nQuels signes cliniques nécessitent une évaluation urgente ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Language+Development&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur 4-Hydroxycoumarines",
"description": "Quels sont les effets secondaires courants des 4-hydroxycoumarines ?\nComment reconnaître une réaction allergique aux 4-hydroxycoumarines ?\nQuels symptômes peuvent indiquer une thrombose malgré le traitement ?\nQuels signes indiquent une surdose de 4-hydroxycoumarines ?\nQuels symptômes nécessitent un ajustement de la dose ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Language+Development&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur 4-Hydroxycoumarines",
"description": "Comment prévenir les complications des 4-hydroxycoumarines ?\nQuelles précautions prendre lors de l'utilisation de 4-hydroxycoumarines ?\nComment éduquer les patients sur les 4-hydroxycoumarines ?\nQuels aliments éviter avec les 4-hydroxycoumarines ?\nComment gérer les interactions médicamenteuses ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Language+Development&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur 4-Hydroxycoumarines",
"description": "Comment traiter une surdose de 4-hydroxycoumarines ?\nQuels médicaments interagissent avec les 4-hydroxycoumarines ?\nQuelle est l'alternative aux 4-hydroxycoumarines ?\nComment ajuster la dose de 4-hydroxycoumarines ?\nQuels sont les traitements de soutien lors d'une surdose ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Language+Development&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur 4-Hydroxycoumarines",
"description": "Quelles sont les complications possibles des 4-hydroxycoumarines ?\nComment gérer une hémorragie due aux 4-hydroxycoumarines ?\nQuels facteurs augmentent le risque de complications ?\nComment prévenir les thromboses sous traitement ?\nQuels signes indiquent une complication grave ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Language+Development&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur 4-Hydroxycoumarines",
"description": "Quels sont les facteurs de risque pour les complications des 4-hydroxycoumarines ?\nComment l'alimentation influence-t-elle l'efficacité des 4-hydroxycoumarines ?\nQuels médicaments augmentent le risque de saignement ?\nComment l'âge affecte-t-il le traitement par 4-hydroxycoumarines ?\nQuels antécédents médicaux sont préoccupants ?",
"url": "https://questionsmedicales.fr/mesh/D015110?mesh_terms=Language+Development&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une surdose de 4-hydroxycoumarines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests de coagulation et l'évaluation des symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour surveiller le traitement par 4-hydroxycoumarines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le temps de prothrombine (TP) et l'INR sont les tests principaux pour surveiller l'efficacité."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une complication du traitement ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements inhabituels, des ecchymoses ou des douleurs abdominales peuvent indiquer une complication."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité des 4-hydroxycoumarines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la réduction des événements thromboemboliques et les résultats des tests de coagulation."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques nécessitent une évaluation urgente ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de saignement grave, comme des hémorragies cérébrales ou gastro-intestinales, nécessitent une évaluation urgente."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants des 4-hydroxycoumarines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent des saignements, des nausées et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique aux 4-hydroxycoumarines ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, des démangeaisons ou un gonflement peuvent indiquer une réaction allergique."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une thrombose malgré le traitement ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs, un gonflement ou une rougeur dans une jambe peuvent indiquer une thrombose persistante."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une surdose de 4-hydroxycoumarines ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements excessifs, des ecchymoses et des douleurs abdominales peuvent indiquer une surdose."
}
},
{
"@type": "Question",
"name": "Quels symptômes nécessitent un ajustement de la dose ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements fréquents ou des résultats d'INR élevés peuvent nécessiter un ajustement de la dose."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications des 4-hydroxycoumarines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance régulière de l'INR et une éducation des patients sont essentielles pour prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre lors de l'utilisation de 4-hydroxycoumarines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les activités à risque de blessure et informer les professionnels de santé de l'utilisation."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur les 4-hydroxycoumarines ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Informer sur les effets secondaires, l'importance des tests de coagulation et les signes d'alerte."
}
},
{
"@type": "Question",
"name": "Quels aliments éviter avec les 4-hydroxycoumarines ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les aliments riches en vitamine K, comme les légumes à feuilles vertes, pour maintenir l'efficacité."
}
},
{
"@type": "Question",
"name": "Comment gérer les interactions médicamenteuses ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consulter un professionnel de santé avant de prendre d'autres médicaments pour éviter les interactions."
}
},
{
"@type": "Question",
"name": "Comment traiter une surdose de 4-hydroxycoumarines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'administration de vitamine K et la surveillance des paramètres de coagulation."
}
},
{
"@type": "Question",
"name": "Quels médicaments interagissent avec les 4-hydroxycoumarines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antibiotiques, des anti-inflammatoires et certains antifongiques peuvent interagir avec ces anticoagulants."
}
},
{
"@type": "Question",
"name": "Quelle est l'alternative aux 4-hydroxycoumarines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticoagulants directs comme le rivaroxaban ou l'apixaban sont des alternatives possibles."
}
},
{
"@type": "Question",
"name": "Comment ajuster la dose de 4-hydroxycoumarines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La dose est ajustée en fonction des résultats de l'INR et des facteurs de risque individuels."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements de soutien lors d'une surdose ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des transfusions de plaquettes et des soins intensifs peuvent être nécessaires en cas de surdose sévère."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des 4-hydroxycoumarines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des hémorragies, des thromboses et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Comment gérer une hémorragie due aux 4-hydroxycoumarines ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut l'arrêt du médicament, l'administration de vitamine K et des soins médicaux appropriés."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les maladies hépatiques et l'utilisation concomitante d'autres anticoagulants augmentent le risque."
}
},
{
"@type": "Question",
"name": "Comment prévenir les thromboses sous traitement ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un suivi régulier et ajuster la dose en fonction des résultats de l'INR pour prévenir les thromboses."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques, des difficultés respiratoires ou des saignements importants indiquent une complication grave."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les complications des 4-hydroxycoumarines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de thrombose, l'âge avancé et les maladies hépatiques sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle l'efficacité des 4-hydroxycoumarines ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en vitamine K peut réduire l'efficacité des 4-hydroxycoumarines."
}
},
{
"@type": "Question",
"name": "Quels médicaments augmentent le risque de saignement ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anti-inflammatoires non stéroïdiens (AINS) et certains antibiotiques peuvent augmenter le risque de saignement."
}
},
{
"@type": "Question",
"name": "Comment l'âge affecte-t-il le traitement par 4-hydroxycoumarines ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent avoir une sensibilité accrue et nécessiter un ajustement de la dose."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux sont préoccupants ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de maladies hépatiques ou de troubles de la coagulation sont préoccupants lors du traitement."
}
}
]
}
]
}
The first 5 years of life are characterized by incredible growth across domains of child development. Drawing from over 50 years of seminal research, this chapter contextualizes recent advances in lan...
The characterization of the phenotype of children with congenital Zika virus syndrome (CZS) is an ongoing process, since many characteristics can only be described with the advancing age of children p...
To describe emerging findings on the impact of CZS on language development in children with CZS in a 4-year longitudinal study....
39 boys and 44 girls with CZS were allocated into four groups according to age ranging from 12 to 36 months. Language development was assessed using the Early Language Milestone Scale....
Visual, expressive, and receptive auditory skills of patients were lower than expected for their age. Despite producing vowel sounds, they did not babble; despite present hearing, the majority of the ...
Most children with CZS are not able to produce vocalic sounds, but some may be able to communicate basic needs through alternative communication. WHAT THIS PAPER ADDS?: Some babies with CZS died prena...
Bilingual children are a more heterogenous group than their monolingual counterparts with respect to the sources of variation in their language learning environments, as well as the wide individual va...
Computational models of reading have tended to focus on the cognitive requirements of mapping among written, spoken, and meaning representations of individual words in adult readers. Consequently, the...
Language development is critical to various outcomes in young children with developmental disabilities (DD), including autism spectrum disorder (ASD) and non-ASD delays. However, language development ...
To investigate the language development trajectories of young children with DD in Taiwan. We investigated the relationship between trajectory class assignment and diagnostic outcomes (ASD or non-ASD d...
The participants were 101 young children with DD (mean age: 21.88 months; follow-up: 1.5 and 3 years after enrollment). Growth mixture modeling analyses were conducted to receptive language developmen...
Three RLDQ trajectories were identified, namely age expected, delayed catch-up, and delayed, and two ELDQ trajectories were identified, namely delayed improve and delayed. Trajectory class assignment ...
Language development in young children with DD in Taiwan is heterogeneous. Delayed receptive and expressive language development trajectories relate to later ASD diagnoses....
While the primary purpose of cochlear implant (CI) fitting is to improve individuals' receptive and expressive skills, musical emotion perception (MEP) is generally ignored. This study assesses the ME...
26 CI users and 26 matched healthy controls between the ages of 6 and 9 were included in the study. The Test of Language Development (TOLD) was applied to evaluate the LS of the participants, and the ...
MEI test scores and all subtests of TOLD were statistically significantly lower in the CI group. Also, there was a statistically significant and moderate correlation between the listening subtest of T...
MEP and language skills are poor in children with CI. Although language skills are primarily targeted in CI performance, improving MEP should also be included in rehabilitation programs. The relations...
The quality of language that children hear in their environment is associated with the development of language-related brain regions, in turn promoting vocabulary knowledge. Although informative, it r...
This study investigates the influence of the quantity, content, and context of screen media use on the language development of 85 Saudi children aged 1 to 3 years. Surveys and weekly event-based diari...
The disruption caused by the COVID-19 pandemic has raised concerns about children's development. Here, we examined the impact of the pandemic on Canadian infants' and toddlers' (N = 539) language deve...
Why are children's first utterances short and ungrammatical, with some obvious constructions missing? What determines the lengthening of children's early utterances over time? The literature is replet...